Genmab A/S (GNMSF)
GNMSF Stock Price Chart
Explore Genmab A/S interactive price chart. Choose custom timeframes to analyze GNMSF price movements and trends.
GNMSF Company Profile
Discover essential business fundamentals and corporate details for Genmab A/S (GNMSF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Jan 2010
Employees
2.64K
Website
https://www.genmab.comCEO
Jan G.J. van de Winkel
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
GNMSF Financial Timeline
Browse a chronological timeline of Genmab A/S corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 10 Feb 2026
Upcoming earnings on 6 Nov 2025
Revenue estimate is $970.74M.
Earnings released on 7 Aug 2025
EPS came in at $5.42 surpassing the estimated $3.99 by +35.84%, while revenue for the quarter reached $145.94M , missing expectations by -84.75%.
Earnings released on 8 May 2025
EPS came in at $3.05 surpassing the estimated $1.87 by +63.10%, while revenue for the quarter reached $725.99M , missing expectations by -3.90%.
Earnings released on 12 Feb 2025
EPS came in at $5.70 surpassing the estimated $0.47 by +1.13K%, while revenue for the quarter reached $891.43M , missing expectations by -0.85%.
Earnings released on 6 Nov 2024
EPS came in at $2.85 falling short of the estimated $3.19 by -10.66%, while revenue for the quarter reached $815.16M , beating expectations by +540.66%.
Earnings released on 8 Aug 2024
EPS came in at $3.18 surpassing the estimated $3.00 by +6.00%, while revenue for the quarter reached $777.83M , beating expectations by +609.77%.
Earnings released on 2 May 2024
EPS came in at $2.91 surpassing the estimated $1.76 by +65.34%, while revenue for the quarter reached $594.93M , beating expectations by +666.17%.
Earnings released on 14 Feb 2024
EPS came in at $3.63 surpassing the estimated $3.33 by +9.01%, while revenue for the quarter reached $690.33M , beating expectations by +2.85%.
Earnings released on 7 Nov 2023
EPS came in at $4.63 surpassing the estimated $2.96 by +56.42%, while revenue for the quarter reached $669.38M , beating expectations by +4.13%.
Earnings released on 3 Aug 2023
EPS came in at $3.03 surpassing the estimated $2.82 by +7.45%, while revenue for the quarter reached $613.29M , beating expectations by +2.02%.
Earnings released on 10 May 2023
EPS came in at $0.50 falling short of the estimated $0.65 by -22.65%, while revenue for the quarter reached $416.08M , beating expectations by +2.86%.
Earnings released on 22 Feb 2023
EPS came in at $1.25 falling short of the estimated $3.92 by -68.11%, while revenue for the quarter reached $754.97M , beating expectations by +11.52%.
Earnings released on 9 Nov 2022
EPS came in at $5.36 surpassing the estimated $2.63 by +103.80%, while revenue for the quarter reached $535.64M , beating expectations by +14.33%.
Earnings released on 10 Aug 2022
EPS came in at $3.95 surpassing the estimated $2.11 by +87.20%, while revenue for the quarter reached $443.98M , beating expectations by +5.82%.
Earnings released on 11 May 2022
EPS came in at $0.99 surpassing the estimated $0.81 by +21.95%, while revenue for the quarter reached $315.14M , beating expectations by +3.32%.
Earnings released on 16 Feb 2022
EPS came in at $1.65 surpassing the estimated $1.51 by +9.27%, while revenue for the quarter reached $399.16M , beating expectations by +2.67%.
Earnings released on 10 Nov 2021
EPS came in at $2.08 surpassing the estimated $1.28 by +62.50%, while revenue for the quarter reached $360.41M , beating expectations by +15.28%.
Earnings released on 11 Aug 2021
EPS came in at $0.73 surpassing the estimated $0.66 by +10.56%, while revenue for the quarter reached $314.36M .
Earnings released on 5 May 2021
EPS came in at $2.69 surpassing the estimated $0.65 by +311.31%, while revenue for the quarter reached $249.78M .
Earnings released on 23 Feb 2021
EPS came in at $1.43 surpassing the estimated $1.30 by +10.00%, while revenue for the quarter reached $335.62M .
Earnings released on 4 Nov 2020
EPS came in at $1.27 , while revenue for the quarter reached $271.70M .
GNMSF Stock Performance
Access detailed GNMSF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.